MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce its wholly-owned subsidiary United Greeneries ("UG") has received notification from Health Canada ("HC") that an MMPR Pre-License Inspection of UG's Duncan Facility will be conducted on February 1, 2016.
MMJ PhytoTech Ltd (ASX:MMJ) are pleased to provide an Investor Presentation titled, 'Farm to Pharma: Maximizing Value Along the Chain'.
MMJ PhytoTech Limited (ASX:MMJ) (the "Company") Management and Board are pleased to announce it has received its first wholesale order for its 10mg and 100mg Satipharm CBD Gelpell(R) Gastro-resistant Microgel Capsules ("CBD Capsules" or "Capsules").
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that through its subsidiary UG, it has received full occupancy at the state-of-the-art Duncan Facility located near Vancouver, British Columbia, Canada. UG was issued an Occupancy Permit as expected on 2 November 2015 after provincial and municipal review and approval.
MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or the "Company") today announces its activities report for the quarter ended 30 September 2015. Focus shifted to execution after successful post-merger integration; strong start to December quarter with unexpected developments positioning the Company well.
MMJ PhytoTech Limited's (ASX:MMJ) Management and Board are pleased to announce the commencement of the Phase 1 Clinical Trials being undertaken in Israel. A summary of the Phase 1 Clinical Trial was released to the market on July 6, 2015.
MMJ PhytoTech Limited (ASX:MMJ) advises that APP Securities Pty Ltd has issued an updated research report which is available on the Company's website.
